FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination with chemotherapy.
Day
May 6, 2021
